MiNK Therapeutics to Participate at Upcoming Investor Conferences

Rhea-AI Summary

MiNK Therapeutics, a biopharmaceutical firm focused on allogeneic iNKT cell therapies for cancer and immune diseases, will participate in two investor conferences this September. The HC Wainwright 24th Annual Global Investment Conference will feature a webcast on September 12th at 7:00 AM ET. Additionally, MiNK will participate in the Baird 2022 Global Healthcare Conference on September 14th at 1:25 PM ET. Both events will allow investors to explore MiNK's innovative therapies. Webcast replays will be available on the Company’s website.

NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, announced that the Company will participate in two investor conferences in September:

• HC Wainwright 24th Annual Global Investment Conference
  Fireside chat webcast will be available beginning at 7:00 AM ET on September 12^th. Registration available at: https://journey.ct.events/view/16e5cc45-7c5a-4f7d-8de1-d0c1b519dfa8

• Baird 2022 Global Healthcare Conference
  Fireside chat will be held at 1:25 PM ET on September 14^th. The conference will take place at the InterContinental New York Barclay.

A webcast replay will be available following the conferences and may be accessed on the Events & Presentations page of the Company’s website at https://investor.minktherapeutics.com/events-and-presentations.

About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. MiNK is advancing a pipeline of both native and next-generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery. The company is headquartered in New York, NY. For more information, please visit https://minktherapeutics.com/.

Contact

Kimberly Ha

KKH Advisors

917-291-5744

kimberly.ha@kkhadvisors.com

FAQ

What are the dates for MiNK Therapeutics' investor conferences in September 2022?

MiNK Therapeutics will participate in two investor conferences on September 12 and September 14, 2022.

What time will the HC Wainwright Conference webcast start?

The HC Wainwright 24th Annual Global Investment Conference webcast will begin at 7:00 AM ET on September 12, 2022.

Where can I find the replay for MiNK Therapeutics' investor conference webcasts?

Replay of the investor conference webcasts will be available on the Events & Presentations page of MiNK Therapeutics' website.

What is MiNK Therapeutics focusing on at the Baird 2022 Global Healthcare Conference?

At the Baird 2022 Global Healthcare Conference, MiNK Therapeutics will discuss their allogeneic iNKT cell therapies for cancer and immune-mediated diseases.

What type of therapies is MiNK Therapeutics developing?

MiNK Therapeutics is developing allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.